Freenome Inc. (FRNM)
NASDAQ: FRNMHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
FRNM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.72B
- EPS (TTM)
- -$2.04
- Dividend yield
- None
- 52-week range
- 9.95 – 17.50
- Day range
- 15.82 – 16.62
- Volume / Avg
- 648.25K / 791.80K
- Beta
- —
- Shares outstanding
- 107.45M
52-week range
FRNM stock today
Shares of Freenome (FRNM) finished lower on Oct 7 at $16.03, a drop of 2.02% or $0.33 per share, versus the S&P 500's 0.22% decline. Shares are 8.4% below their 52-week high of $17.50, set on Sep 21, 2026 and 61.1% above the 52-week low of $9.95, near the top of the past year's range. FRNM is up 23.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 51.2%.
Freenome has posted a net loss over the last twelve months (EPS of -$2.04), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Freenome
Company profileFreenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Aaron Elliott Ph.D.
- Headquarters
- Brisbane, CA
- Employees
- 375
- Website
- freenome.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$18.00+12.29%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Freenome peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PSNLPersonalis Inc. | 16.00 | -0.19% | $1.71B | vs FRNM |
| ALHCAlignment Healthcare Inc. | 8.55 | +2.15% | $1.77B | vs FRNM |
| FTREFortrea Holdings Inc. | 20.56 | -1.06% | $1.96B | vs FRNM |
| TRUPTrupanion Inc. | 24.63 | -0.20% | $1.07B | vs FRNM |
| CLOVClover Health Investments Corp. Class A | 4.56 | -0.87% | $2.42B | vs FRNM |
| LMRILumexa Imaging Holdings Inc. | 10.59 | -1.12% | $1.02B | vs FRNM |
| CSTLCastle Biosciences Inc. | 33.00 | -1.08% | $1.01B | vs FRNM |
| ACHCAcadia Healthcare Company Inc. | 29.23 | +0.65% | $2.72B | vs FRNM |
Indexes, lists and sector
Freenome stock FAQ
What is Freenome's stock price today?
FRNM last traded at $16.03 as of Oct 7, 4:00 PM EDT, down 2.02% on the day. Prices are delayed at least 15 minutes.
Who is Freenome's CEO?
Mr. Aaron Elliott Ph.D. is the chief executive officer of Freenome Inc., which has about 375 employees.
What is the FRNM 52-week high?
The 52-week high for FRNM is $17.50 and the 52-week low is $9.95. The stock is currently 8.4% below its high.